statin potency chart

A List of Statins – Dosing Range and Potency. Am J Cardiol. The Expert Panel's treatment recommendations are divided into several major categories and are summarized in Table 2. Not Completely: Why It Is Right to Drop LDL-C Targets, but Wrong to Recommend Statins at a 7.5% 10-Year Risk, Related POEM: 2013 ACC/AHA Cholesterol Guideline Greatly Increases Number Eligible for Statin Treatment. This can lead to severe muscle pain and kidney damage. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Patients with primary LDL-C levels of 190 mg per dL or greater, 3. Liver damage. ¶—Levels of evidence: A = multiple populations evaluated (data derived from multiple randomized clinical trials or meta-analyses); B = limited populations evaluated (data derived from a single randomized trial or nonrandomized studies); C = very limited populations evaluated (only consensus opinion of experts, case studies, or standard of care). Adapted with permission from Stone NJ, Robinson JG, Lichtenstein AH, et al. Very rarely, high-dose statin use can cause muscle cells to break down and release a protein called myoglobin into the bloodstream. The Expert Panel did not find evidence to support the use of specific LDL-C or non–high-density lipoprotein cholesterol (HDL-C) target levels. To see the full article, log in or purchase access. For example, for persons in this age group, the estimated 10-year risk is 7.5% or greater, which is a risk threshold for which a reduction in ASCVD events has been demonstrated in RCTs. When choosing a statin dose, expected LDL reduction is not the only factor to consider. (ACC = American College of Cardiology; AHA = American Heart Association; ASCVD = atherosclerotic cardiovascular disease; LDL-C = low-density lipoprotein cholesterol.). If the increase is mild, you can continue to take the drug. Less evidence is available to support nonstatin therapy for ASCVD prevention. If high-intensity statins are not tolerated, the maximum tolerated intensity should be used. Circulation. When initiating moderate- or high-intensity statin therapy in persons older than 75 years who have clinical ASCVD, it is reasonable to evaluate for potential risk-reduction benefits, adverse effects, and drug-drug interactions. 2003 Jul 15;92(2):152-60. Don't miss a single issue. The Pooled Cohort Equations are recommended to estimate the 10-year risk and lifetime risk of ASCVD in white and black adults, with the goal of identifying high-risk persons who will benefit from statin therapy. Copyright © 2014 by the American Academy of Family Physicians. No, Published source: Circulation, June 24, 2014, Available at: http://circ.ahajournals.org/content/129/25_suppl_2/S1, Endorsed with qualifications by the AAFP, June 2014: https://www.aafp.org/patient-care/clinical-recommendations/all/cholesterol.html, MARA LAMBERT, AFP Senior Associate Editor. Appendix A: Grouping of statins. Available as generic in the U.S.? High-intensity statins should be used unless contraindicated. 2014 Aug 15;90(4):260-265. Decades of research have demonstrated an association between high levels of low-density lipoprotein cholesterol (LDL-C) and an increased risk of atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease, stroke, and peripheral arterial disease. ASCVD = atherosclerotic cardiovascular disease; COE = class of recommendation||; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; LOE = level of evidence¶; RCTs = randomized controlled trials. Get concise advice on drug therapy, plus unlimited access to CE. In men and women up to 75 years of age who have clinical ASCVD, high-intensity statin therapy should be initiated unless contraindicated. / afp Published LDL-cholesterol reducing potency. †—Estimated 10-year or “hard” ASCVD risk includes first occurrence of nonfatal myocardial infarction, coronary heart disease death, and nonfatal and fatal stroke as used by the Risk Assessment Work Group in developing the Pooled Cohort Equations (see http://my.americanheart.org/cvriskcalculator and http://www.cardiosource.org/science-and-quality/practice-guidelines-and-quality-standards/2013-prevention-guideline-tools.aspx). Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP. The single best solution for statin side effects. 90/No. Daily dosage range. 4(August 15, 2014) note: Specific statins and dosages noted in bold were evaluated in RCTs included in critical question 1, critical question 2, and the Cholesterol Treatment Trialists 2010 meta-analysis included in critical question 3 (see full guideline for details).